Predicted protein targets (top 4)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ITGB2 | P05107 | 20/20 | 0.87 |
| ▸ | ICAM1 | P05362 | 20/20 | 0.87 |
| ▸ | ITGAL | P20701 | 20/20 | 0.87 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.87 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20833710 | 1.00 | ITGB2 (0.87) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL22476466 | 0.94 | ITGB2 (0.78) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL20833713 | 0.94 | ITGB2 (0.87) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL23422265 | 0.94 | ITGB2 (0.89) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL29720428 | 0.94 | ITGB2 (0.89) | ITGB2ICAM1ITGALCYP2C9 | |
| SCHEMBL20833718 | 0.94 | ITGB2 (0.89) | ITGB2ICAM1ITGALCYP2C9 | |
| Lifitegrast SCHEMBL31010393 | 0.93 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| Lifitegrast SCHEMBL2632068 | 0.93 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| Lifitegrast SCHEMBL22556043 | 0.93 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 | |
| Lifitegrast SCHEMBL29355715 | 0.93 | ITGB2 (1.00) | ITGB2ICAM1ITGALCYP2C9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 58 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3807268-B1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | OLON SPA (IT) | 2024-01-24 | — | — | EP | disclosed |
| US-20230331711-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | BAUSCH + LOMB IRELAND LIMITED (IE) | 2023-10-19 | — | — | US | disclosed |
| US-20230331711-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | BAUSCH + LOMB IRELAND LIMITED (IE) | 2023-10-19 | — | — | US | disclosed |
| US-11345683-B2 | Process for the preparation of lifitegrast | AUROBINDO PHARMA LTD (IN) | 2022-05-31 | — | — | US | disclosed |
| US-20220073500-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2022-03-10 | — | — | US | disclosed |
| US-20210246123-A1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | OLON S.P.A. (IT) | 2021-08-12 | — | — | US | disclosed |
| US-11028077-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2021-06-08 | — | — | US | disclosed |
| US-11001574-B2 | Process to obtain a tetrahydroisoquinoline derivative | MEDICHEM S.A. (ES) | 2021-05-11 | — | — | US | disclosed |
| US-20210032226-A1 | A PROCESS FOR THE PREPARATION OF LIFITEGRAST | AUROBINDO PHARMA LTD (IN) | 2021-02-04 | — | — | US | disclosed |
| US-10906892-B2 | LFA-1 inhibitor and methods of preparation and polymorph thereof | NOVARTIS PHARMACEUTICALS CORPORATION (US) | 2021-02-02 | — | — | US | disclosed |
| US-20130144063-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARCODE BIOSCIENCE INC. (US) | 2013-06-06 | — | — | US | disclosed |
| US-8378105-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8378105-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2013-02-19 | — | — | US | disclosed |
| US-8367701-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-8367701-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2013-02-05 | — | — | US | disclosed |
| US-20120107404-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARCODE BIOSCIENCE INC. (US) | 2012-05-03 | — | — | US | disclosed |
| US-8080562-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-8080562-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | SARCODE BIOSCIENCE INC. (US) | 2011-12-20 | — | — | US | disclosed |
| US-20110092707-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | SARCODE CORPORATION (US) | 2011-04-21 | — | — | US | disclosed |
| US-20090298869-A1 | Crystalline pharmaceutical and methods of preparation and use thereof | CITIBANK, N.A., AS NOTES COLLATERAL AGENT | 2009-12-03 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (12 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11345683-B2 | Process for the preparation of lifitegrast | LIFR, IDUA, LMTK2 | ITGB2 1113/4885ICAM1 4692/4885ITGAL 1125/4885 |
| US-11028077-B2 | Crystalline pharmaceutical and methods of preparation and use thereof | VCAM1, ICAM1, HLA-DRB1 | ITGB2 14/4885ICAM1 2/4885ITGAL 8/4885 |
| US-20120107404-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | VCAM1, ICAM1, HLA-DRB1 | ITGB2 14/4885ICAM1 2/4885ITGAL 8/4885 |
| US-20220073500-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | VCAM1, ICAM1, HLA-DRB1 | ITGB2 14/4885ICAM1 2/4885ITGAL 8/4885 |
| US-20130144063-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | VCAM1, ICAM1, HLA-DRB1 | ITGB2 14/4885ICAM1 2/4885ITGAL 8/4885 |
| US-20090298869-A1 | Crystalline pharmaceutical and methods of preparation and use thereof | VCAM1, ICAM1, HLA-DRB1 | ITGB2 14/4885ICAM1 2/4885ITGAL 8/4885 |
| US-20210246123-A1 | PROCESS FOR THE PREPARATION OF LIFITEGRAST | LIFR, FLT3, F12 | ITGB2 908/4885ICAM1 4588/4885ITGAL 590/4885 |
| US-20230331711-A1 | CRYSTALLINE PHARMACEUTICAL AND METHODS OF PREPARATION AND USE THEREOF | VCAM1, ICAM1, HLA-DRB1 | ITGB2 14/4885ICAM1 2/4885ITGAL 8/4885 |
| US-20110092707-A1 | Crystalline Pharmaceutical and Methods of Preparation and Use Thereof | VCAM1, ICAM1, HLA-DRB1 | ITGB2 14/4885ICAM1 2/4885ITGAL 8/4885 |
| US-20210032226-A1 | A PROCESS FOR THE PREPARATION OF LIFITEGRAST | LIFR, BDKRB2, IDUA | ITGB2 1203/4885ICAM1 4590/4885ITGAL 1297/4885 |
| US-11001574-B2 | Process to obtain a tetrahydroisoquinoline derivative | KCNQ5, KCNQ4, KCNQ2 | ITGB2 3390/4885ICAM1 4655/4885ITGAL 2789/4885 |
| US-10906892-B2 | LFA-1 inhibitor and methods of preparation and polymorph thereof | ITGB1, ITGA1, VCAM1 | ITGB2 10/4885ICAM1 7/4885ITGAL 4/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.